Fundamentals data is not available for this company.
Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-25 | 329.39 | 8.79 | (34.84)¢ | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-26 | 384.83 | 49.07 | 45.13¢ | 23.4 | n/a | n/a | n/a | 0.0% |
31-Dec-27 | 440.01 | 79.77 | 62.95¢ | 16.8 | 0.4 | +40% | n/a | 0.0% |
Copyright © 2025 FactSet Research Systems Inc. All rights reserved.
No recent information was found.
Dynavax, Merck team up on hepatitis B vaccine | 02-Nov-2007 | BayArea.com |
Merck Buys License to Sell New Vaccine for Hepat... | 01-Nov-2007 | New York Times |
Business Digest | 20-Jan-2006 | BayArea.com |
Currency | US Dollars |
Share Price | $ 10.58 |
Change Today | $ -0.32 |
% Change | -2.94 % |
52 Week High | $14.40 |
52 Week Low | $9.51 |
Volume | 3,840,929 |
Shares Issued | 65.06m |
Market Cap | $688.38m |
RiskGrade | 699 |
Strong Buy | 1 |
Buy | 3 |
Neutral | 0 |
Sell | 1 |
Strong Sell | 0 |
Total | 5 |
Time | Volume / Share Price |
16:00 | 278,628 @ $10.58 |
15:59 | 100 @ $10.57 |
15:59 | 300 @ $10.57 |
15:59 | 1,237 @ $10.57 |
15:59 | 700 @ $10.57 |
You are here: research